4/A//SEC Filing
SANDERLING VENTURES MANAGEMENT V 4/A
Accession 0001209191-12-057176
CIK 0001235007other
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 5:13 PM ET
Size
10.9 KB
Accession
0001209191-12-057176
Insider Transaction Report
Form 4/AAmended
ENDOCYTE INCECYT
SANDERLING VENTURES MANAGEMENT V
10% Owner
Transactions
- Purchase
Common Stock
2011-12-20$3.20/sh+1,589$5,085→ 32,355 total(indirect: By Sanderling Ventures Management VI) - Purchase
Common Stock
2011-12-21$3.16/sh+1,589$5,021→ 33,944 total(indirect: By Sanderling Ventures Management VI)
Holdings
- 149,003(indirect: By Sanderling Ventures Management V)
Common Stock
Sanderling Ventures Management VI
10% Owner
Transactions
- Purchase
Common Stock
2011-12-20$3.20/sh+1,589$5,085→ 32,355 total(indirect: By Sanderling Ventures Management VI) - Purchase
Common Stock
2011-12-21$3.16/sh+1,589$5,021→ 33,944 total(indirect: By Sanderling Ventures Management VI)
Holdings
- 149,003(indirect: By Sanderling Ventures Management V)
Common Stock
Footnotes (4)
- [F1]The form 4 is being amended to correct the number of shares acquired and the number of shares beneficially owned by the reporting persons following the acquisitions which was incorrectly reported in original filing.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.14 to $3.27, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Fred Middleton is the owner of Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership and he may be deemed to have voting and investment power over shares held of record by Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership. Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.10 to $3.21, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
ENDOCYTE INC
CIK 0001235007
Entity typeother
Related Parties
1- filerCIK 0001267980
Filing Metadata
- Form type
- 4/A
- Filed
- Dec 11, 7:00 PM ET
- Accepted
- Dec 12, 5:13 PM ET
- Size
- 10.9 KB